Asarina Pharma, a Stockholm, Sweden-based drug development company focused on the development of a novel therapy for severe premenstrual symptoms, raised €7m in funding.
Backers included new investors Idinvest Partner and Ergomed plc as well as undisclosed existing shareholders.
Led by Peter Nordkild, CEO, Asarina Pharma focuses on the development of Sepranolone (UC1010) for the treatment of premenstrual dysphoric disorder and other menstrually related conditions, which has shown promising results in an exploratory clinical Phase I/II study.
The company intends to use the funds for the continued clinical development of Sepranolone and to prepare a Phase IIb clinical trial, to be conducted in the US and a number of European countries, including Sweden.
FinSMEs
07/11/2016